Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Maat Pharma's Shareholder Yield % was -37.89%.
Maat Pharma (XPAR:MAAT) Shareholder Yield % Explanation
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Maat Pharma Shareholder Yield % Related Terms
Maat Pharma Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Maat Pharma's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:MAAT vs VRTX, REGN, ALNY: Shareholder Yield % Comparison
For the Biotechnology subindustry, Maat Pharma's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maat Pharma Shareholder Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maat Pharma's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Maat Pharma's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Maat Pharma (XPAR:MAAT) has a Shareholder Yield % of -37.89% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Maat Pharma and its competitors. According to the industry distribution chart, Maat Pharma ranks #1129 out of 1297 companies in the Biotechnology industry, placing it in the top 87%.
Is Maat Pharma's Shareholder Yield % too high?
Maat Pharma's current Shareholder Yield % is -37.89%. Based on the distribution chart, Maat Pharma ranks #1129 out of 1297 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Maat Pharma has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Maat Pharma's Shareholder Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Maat Pharma ranks #1129 out of 1297 companies for Shareholder Yield %. This places Maat Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Maat Pharma and its competitors. Maat Pharma's current Shareholder Yield % is -37.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maat Pharma stock overvalued right now?
Based on GuruFocus' analysis, Maat Pharma (XPAR:MAAT) is currently considered Possible Value Trap. The stock's GF Value™ is €10.63, compared to a current price of €2.73 — trading 74.4% below its estimated fair value. The current Shareholder Yield % is -37.89%. Maat Pharma's overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Maat Pharma (XPAR:MAAT), the current Shareholder Yield % is -37.89% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maat Pharma (XPAR:MAAT) Overvalued in 2026?
Based on GuruFocus' analysis, Maat Pharma stock appears to be undervalued.
The current stock price of €2.73 is trading 74.4% below its estimated GF Value™ of €10.63.
GuruFocus considers Maat Pharma to be Possible Value Trap.
Key valuation signals for XPAR:MAAT:
Shareholder Yield %: -37.89%
GF Value™: €10.63 vs. price of €2.73 (74.4% below fair value)
No single metric tells the full story. See the XPAR:MAAT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maat Pharma SA is a french clinical stage biotech and a pioneer in the development of microbiome based ecosystem therapies dedicated to improving survival outcomes for patients with cancer.
27GF Score
Get the complete analysis for XPAR:MAAT
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MAAT has been successfully added to your 
